Drug Profile
Research programme: PDZ domain inhibitors - Avilex Pharma
Latest Information Update: 08 Jan 2021
Price :
$50
*
At a glance
- Originator Avilex Pharma
- Class Analgesics; Antihaemorrhagics; Dipeptides; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action PDZ domain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Stroke; Subarachnoid haemorrhage
- No development reported Neuropathic pain
Most Recent Events
- 12 Oct 2020 Early research in Stroke in Denmark (Parenteral) before October 2020
- 12 Oct 2020 Early research in Subarachnoid haemorrhage in Denmark (Parenteral) before October 2020
- 16 Jul 2016 No recent reports of development identified for research development in Neuropathic-pain in Denmark